Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

PSTV

Live52w high -71.9%

Annual Quarterly

Core line items from PSTV's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: PLUS THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-12	Q1 2019 2019-03-31	Annual 2018 2018-12-31	Q3 2018 2018-09-30	Q1 2018 2018-03-31
Revenue	$1.39M	$703.00K	$3.67M	$2.25M	$731.00K
Operating Income	Not available	$-2.17M	$-8.76M	$-6.85M	$-4.35M
Net Income	Not available	$-3.15M	$-12.63M	$-10.40M	$-4.41M
EPS (Diluted)	$-0.87	Not available	Not available	Not available	Not available
Total Assets	Not available	$24.62M	$23.99M	$25.53M	$26.64M
Total Liabilities	Not available	$20.76M	$18.77M	$19.39M	$18.16M
Cash & Equivalents	Not available	$3.87M	$5.26M	$6.81M	$5.90M
Free Cash Flow OCF − CapEx	Not available	$-3.28M	$-12.11M	$-9.62M	$-4.17M
Shares Outstanding	Not available	14.83M	296.61K	11.69M	61.61M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from PSTV's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -71.9%

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: PLUS THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-12	Q1 2019 2019-03-31	Annual 2018 2018-12-31	Q3 2018 2018-09-30	Q1 2018 2018-03-31
Revenue	$1.39M	$703.00K	$3.67M	$2.25M	$731.00K
Operating Income	Not available	$-2.17M	$-8.76M	$-6.85M	$-4.35M
Net Income	Not available	$-3.15M	$-12.63M	$-10.40M	$-4.41M
EPS (Diluted)	$-0.87	Not available	Not available	Not available	Not available
Total Assets	Not available	$24.62M	$23.99M	$25.53M	$26.64M
Total Liabilities	Not available	$20.76M	$18.77M	$19.39M	$18.16M
Cash & Equivalents	Not available	$3.87M	$5.26M	$6.81M	$5.90M
Free Cash Flow OCF − CapEx	Not available	$-3.28M	$-12.11M	$-9.62M	$-4.17M
Shares Outstanding	Not available	14.83M	296.61K	11.69M	61.61M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.